SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001088856

CORT

CORCEPT THERAPEUTICS INC
$116.49 ▲ +2.16%
Prev close $114.03
Market cap$12.6B
ConsensusStrong Buy
12-mo target$141.00 (+21.1%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)35 New Institutional Positions15 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CORT right now — valuation, ownership and activity at a glance.
Market Cap
$12.6B
Cap Size
Large Cap
Analyst Consensus
Strong Buy (83%)
Inst. Holders
50 funds
Inst. Value
$5.2B
Inst. Activity
35 buys / 15 sells
Insider Activity
$0.00 buy / $31.0M sell
Insider Net $
-$31.0M
Social Sentiment
50° Neutral
SEC Reports
20
Price chart 30d +5.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Dec 17, 2026 fda_pdufa
PDUFA: CORT — relacorilant in Cushing's syndrome — 2026-12-17
FDA target action date 2026-12-17 for CORT (CORCEPT THERAPEUTICS INC). Drug: relacorilant. Indicatio
Sep 24, 2026 Insider
Robb Gary Charles gifted 5,000 shares
Chief Business Officer
Sep 24, 2026 Insider
Robb Gary Charles gifted 17,100 shares
Chief Business Officer
Sep 17, 2026 Insider
Robb Gary Charles acquired via exercise 17,493 shares
Chief Business Officer @ $8.27 ($144.7K)
Sep 4, 2026 SEC
Two Corcept Therapeutics insiders sold a combined $4.01M in stock over a week, including a Director's $3.27M sale. The t
CLUSTER — Impact 2/10
Aug 29, 2026 SEC
Two Corcept Therapeutics insiders — Director Kimberly Park and executive Sean Maduck — sold a combined $4.01M in open-ma
CLUSTER — Impact 2/10
Aug 28, 2026 SEC
Two Corcept Therapeutics insiders sold a total of ~$788K in shares over a week, with the bulk ($740K) from Sean Maduck (
CLUSTER — Impact 2/10
Jul 23, 2026 Event
Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. et al
Court ruling (cand) — Docket: 5:24-cv-03567
Analyst ratings buy % +10.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 83% rate it Buy or better · 12 analysts
Strong Buy 3 25% Buy 7 58% Hold 1 8% Sell 0 0% Strong Sell 1 8%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 18, 2026HC Wainwright & Co.REITERATEBuy 43%
Jul 30, 2026Piper SandlerREITERATEOverweight 54%
Jul 30, 2026Canaccord GenuityMAINTAINBuy 47%
Jul 30, 2026HC Wainwright & Co.MAINTAINBuy 43%
Jul 29, 2026Canaccord GenuityMAINTAINBuy 47%
Jul 27, 2026Wolfe ResearchDOWNGRADEUnderperform 52%
May 28, 2026Canaccord GenuityMAINTAINBuy 47%
May 28, 2026HC Wainwright & Co.MAINTAINBuy 43%
May 13, 2026UBSUPGRADEBuy 55%
May 4, 2026HC Wainwright & Co.MAINTAINBuy 43%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20263710183%
Aug 1, 20263710183%
Jul 1, 20262820083%
Jun 1, 20262820083%
May 1, 20262730075%
Apr 1, 20262730075%
Mar 1, 20262720175%
Feb 1, 20262720175%
Price targets
Where 5 covering analysts think CORT trades over the next 12 months.
$141.00 +21.1% upside Strong Buy
Current$116.44 Low$50.00 Median$164.00 High$165.00 5 analysts
$50.00$165.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
2 mentions 0 bullish 0 bearish 2 neutral
Recent posts
wallstreetbets Neutral 4mo ago
CASE STUDY CORT
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 4 bullish, 2 bearish, 0 mixed, 14 neutral · avg impact 3.5/10.
NEUTRALCLUSTER2/10
Two Corcept Therapeutics insiders sold a combined $4.01M in stock over a week, including a Director'
Sep 4, 2026
NEUTRALCLUSTER2/10
Two Corcept Therapeutics insiders — Director Kimberly Park and executive Sean Maduck — sold a combin
Aug 29, 2026
NEUTRALCLUSTER2/10
Two Corcept Therapeutics insiders sold a total of ~$788K in shares over a week, with the bulk ($740K
Aug 28, 2026
NEUTRALCLUSTER4/10
A cluster of insider selling at Corcept Therapeutics, led by Director David Mahoney ($12.2M) and CBO
Aug 21, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Dec 17, 2026
fda_pdufa
PDUFA: CORT — relacorilant in Cushing's syndrome — 2026-12-17
FDA target action date 2026-12-17 for CORT (CORCEPT THERAPEUTICS INC). Drug: relacorilant. Indication: Cushing's syndrome. PDUFA target action date fo
Sep 28, 2026
Clinical Trial
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Phase Phase 2 — COMPLETED
Sep 18, 2026
short_volume
Short Volume: CORT — 69.3% short (0.6M / 0.8M)
Short: 577,187 | Exempt: 5,407 | TRF Vol: 833,453 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
Clinical Trial
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Sep 14, 2026
clinical_trial_readout
T-90d Trial Readout: relacorilant (Phase 2)
Trial: Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Sponsor: Corcept Therapeutics Phase:
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$0.86$0.74–$1.03440.6%+241.5%1↑ 0↓$0.3B4
Next Q$1.21$1.01–$1.31502.5%+109.0%1↑ 0↓$0.4B4
Current FY$2.15$1.84–$2.41162.2%+286.2%1↑ 0↓$1.1B4
Next FY$4.40$1.85–$7.75104.8%+37.3%2↑ 0↓$1.7B4
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$0.865—
7d ago$0.850+0.015
30d ago$0.253+0.612
60d ago$0.253+0.612
90d ago$0.250+0.615
Institutional ownership
Which big funds own CORT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $5.2B total value (59,310,882 shares) as of 2026-Q2. Top holders: BlackRock,, RENAISSANCE, VANGUARD. Net buying activity: 35 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.12,432,023$1.1B21.0%—
RENAISSANCE TECHNOLOGIES LLC5,261,628$457.5M8.9%—
VANGUARD PORTFOLIO MANAGEMENT LLC5,044,638$438.6M8.5%—
VANGUARD CAPITAL MANAGEMENT LLC4,172,482$362.8M7.0%—
FMR LLC3,337,618$290.2M5.6%—
STATE STREET CORP3,279,381$285.2M5.5%—
AQR CAPITAL MANAGEMENT LLC2,582,561$224.6M4.4%—
GEODE CAPITAL MANAGEMENT, LLC2,532,198$220.2M4.3%—
FIRST TRUST ADVISORS LP1,829,545$159.1M3.1%—
UBS Group AG1,377,658$119.8M2.3%—
Recent position changes
FundActionPrevCurrentChangeValue
D. E. Shaw & Co., Inc.TRIM1,181,348883,001-25.3%$76.8M
FULLER & THALER ASSET MANAGEMENT, INC.NEW—710,106—$61.7M
JACOBS LEVY EQUITY MANAGEMENT, INCNEW—695,532—$60.5M
Allspring Global Investments Holdings, LLCDOUBLED214,572523,192+143.8%$46.3M
NORGES BANKNEW—487,055—$42.3M
Nuveen, LLCDOUBLED191,904388,078+102.2%$33.7M
BANK OF AMERICA CORP /DE/DOUBLED111,736328,565+194.1%$28.6M
JPMORGAN CHASE & COADD200,953253,182+26.0%$22.7M
CANADA PENSION PLAN INVESTMENT BOARDTRIM324,901191,101-41.2%$16.6M
CAPITAL FUND MANAGEMENT S.A.ADD126,429184,231+45.7%$16.0M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$31.0M — $0.00 bought, $31.0M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 24, 2026Robb Gary CharlesChief Business OfficerGIFT5,000——
Sep 24, 2026Robb Gary CharlesChief Business OfficerGIFT17,100——
Sep 17, 2026Robb Gary CharlesChief Business OfficerEXERCISE17,493$8.27$144.7K
Sep 16, 2026Vieira Roberto WandenkolkPresident, OncologySELL296$100.82$29.8K
Sep 15, 2026WILSON JAMES NDirectorSELL6,800$110.27$749.8K
Sep 15, 2026WILSON JAMES NDirectorSELL400$110.84$44.3K
Sep 15, 2026WILSON JAMES NDirectorSELL2,800$111.70$312.8K
Sep 14, 2026Lyon Joseph DouglasSee RemarksEXERCISE7,404$13.56$100.4K
Sep 14, 2026Lyon Joseph DouglasSee RemarksEXERCISE2,596$11.35$29.5K
Sep 14, 2026Lyon Joseph DouglasSee RemarksSELL7,812$113.32$885.3K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CORT.
Shares short
9,350,914
Settlement Sep 15, 2026
Change vs prior
-0.5%
Semi-monthly cycle
Days to cover
9.9
At avg daily volume
Of shares outstanding
≈8.7%
Estimate — not % of float
All CORT filing & press-release reports (26)